OSTX · OS Therapies Inc
$1.75
+0.04 (+2.34%)
At close · Sep 3
Going-concern doubt
— flagged Aug 14, 2026
Substantial doubt about the company's ability to continue as a going concern.
“These factors raise substantial doubt about the Company's ability to continue as a going concern within one year after the date that the unaudited consolidated financial statements are issued.”View the 10-Q filed Aug 14, 2026
Market Cap
$76.57M
Shares
46.13M
OSTX metrics
46 of 114 screener metrics currently available.
Market overview
2 metricsShare price
$1.71
Market cap
$76.57M
Price action
19 metricsPrice change (1W)
+0.6%
Price change (30D)
+7.1%
Price change (3M)
-9.3%
Price change (6M)
+18.6%
Price change (YTD)
+18.6%
Price change (1Y)
-30.5%
Trailing year
Price change (5Y)
—
52-week high
$2.31
52-week low
$1.16
Change from 52-week high
-28.1%
Change from 52-week low
+43.1%
Annualized volatility
72.8%
Beta
1.7
RSI (14D)
54.3
Price vs SMA 50
+1.9%
Price vs SMA 200
+4.7%
Avg volume (3M)
563,665
Relative volume
0.7
Average dollar volume
$963,353
Company
3 metricsSector
Healthcare
Industry
Biotechnology
Shares outstanding
46.13M
Valuation
12 metricsP / E (TTM)
—
Trailing earnings
PEG ratio
—
EV / revenue
—
EV / EBITDA
—
EV / EBIT
—
P / sales
—
P / book
—
FCF yield
—
TTM · current market cap
Buyback yield
—
P / FCF
—
P / operating cash flow
—
Earnings yield
-51.4%
Historical valuation
8 metricsP / E historical average (3Y)
—
P / E historical average (5Y)
—
EV / revenue historical average (3Y)
—
EV / revenue historical average (5Y)
—
EV / EBIT historical average (3Y)
—
EV / EBIT historical average (5Y)
—
EV / EBITDA historical average (3Y)
—
EV / EBITDA historical average (5Y)
—
Dividends & buybacks
7 metricsDividend yield
—
Trailing 12 months
Payout ratio
—
Shareholder yield
—
Dividend / share (TTM)
—
Dividend growth YoY
—
Dividend growth streak
—
Last ex-dividend
—
Earnings calendar
2 metricsNext earnings
—
Last earnings
—
Profitability
9 metricsGross margin
—
Operating margin
—
Trailing 12 months
Net margin
—
Gross profit (TTM)
—
Operating profit (TTM)
−$37.61M
Net income (TTM)
−$39.37M
Trailing 12 months
Diluted EPS (TTM)
$-1.08
FCF margin
—
Effective tax rate
—
Growth
11 metricsRevenue growth YoY
—
Year over year
Net income growth YoY
—
Revenue (TTM)
—
Trailing 12 months
EPS growth YoY
—
Shares change YoY
+74.8%
Year over year · more shares
Revenue CAGR (3Y)
—
Revenue CAGR (5Y)
—
EPS CAGR (3Y)
—
EPS CAGR (5Y)
—
FCF CAGR (3Y)
—
FCF CAGR (5Y)
—
Quality
14 metricsReturn on equity
—
Return on assets
-397.8%
Debt / equity
—
Current ratio
0.2
EBITDA (TTM)
—
Free cash flow (TTM)
—
Quick ratio
0.2
Interest coverage
—
Net debt / EBITDA
—
Return on invested capital
—
Trailing 12 months
Net cash
—
Latest balance sheet
Cash & equivalents
$205,035
Total assets
$9.90M
Total debt
$250,000
Cash flow & spend
7 metricsOperating cash flow (TTM)
−$18.53M
Capital expenditures (TTM)
$466,423
R&D (TTM)
$25.98M
SG&A (TTM)
—
Stock compensation (TTM)
$5.19M
R&D / revenue
—
Stock compensation / revenue
—
Ownership (13F)
3 metrics13F filers
29
13F filer change QoQ
0
Institutional ownership
6.3%
Short interest
3 metricsShort interest
5.6%
Latest settlement · 9.1 days to cover
Days to cover
9.1d
Short-squeeze score
62 / 100
Insider activity
2 metricsNet insider buying (90D)
—
Insider-sentiment score
—
Risk flags
1 metricsGoing concern
Flagged
Key facts
CIK
1795091
CUSIP
68764Y207
13F (30d)
27 filings
27 filers
Visit website
Investor relations